reconstitute cagrilintide 10mg GMP Cagrilintide 10mg - Peptas
Description
rda naukowe Sikiric P, Seiwerth S, Rucman R, et al
J Immunother Cancer 4:111 Kind F, Michalski K, Yousefzadeh-Nowshahr E, Meyer PT, Mix M, Ruf J (2022) Bone marrow impairment during early [177Lu] PSMA-617 radioligand therapy: haematotoxicity or tumour progression
All purchasers must be 18 years of age or older
The substantial Phase I loading dose aims to minimize this translational failure for TB-500
